Tobacco & Nicotine: Vital Statistics Addiction and Treatment - - PDF document

tobacco nicotine
SMART_READER_LITE
LIVE PREVIEW

Tobacco & Nicotine: Vital Statistics Addiction and Treatment - - PDF document

Tobacco & Nicotine: Vital Statistics Addiction and Treatment 47 million US smokers Tim McAfee, MD, MPH 440,000 deaths/year Chief Medical Officer - Free & Clear >8 million disabled 206-876-2551 - tim.mcafee@freeclear.com


slide-1
SLIDE 1

1

Tobacco & Nicotine: Addiction and Treatment

Tim McAfee, MD, MPH Chief Medical Officer - Free & Clear 206-876-2551 - tim.mcafee@freeclear.com Affiliate Assistant Professor, University

  • f Washington, School of Public Health

Vital Statistics

  • 47 million US smokers
  • 440,000 deaths/year
  • >8 million disabled
  • Smokers die ~ 8-13

years earlier

  • 5 million smoking

deaths/year in world

More than 440,000 Annual Deaths Attributable to Cigarette Smoking—United States

Lung Cancer 125,000 Other Cancers 31,000 Chronic Lung Disease 82,000 Stroke 17,000 Ischemic Heart Disease 82,000 Other Diagnoses 105,000

Source: MMWR, 2005

19+ % of Americans smoke tobacco 70+% want to quit Of those making a quit attempt: ~20% use a medication ~2% use behavioral support

Quitting Stats

One in 20 quit attempts succeed

Years of life gained Age at cessation (years)

  • Prospective study of 34,439 male British MDs
  • Mortality monitored for 50 years (1951–2001)

Impact of Quitting Smoking

Doll et al. (2004). BMJ 328(7455):1519–1527

Sir Richard Doll 1912 – 2005

Addiction

slide-2
SLIDE 2

2

Nicotine

  • Tertiary amine

– pyridine and pyrrolidine ring – strongly alkaline

  • Evolved as insecticide in tobacco
  • Binds to nicotinic-cholinergic

receptors

– stimulus effect in locus ceruleus – reward effect in limbic system – releases acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone & ACTH

The Masters Speak…

  • “We are in the business of

selling nicotine, an addictive drug effective in the release of stress mechanisms”

Brown & Williamson, VP Addison Yeaman, 1963

Your turn…

  • Is nicotine addictive?
  • How is it different and the same as
  • ther substances classically

thought of as addictive?

Drug Dependence Criteria

  • Tolerance
  • Psychoactive effects
  • Withdrawal
  • Use despite harm to self or others
  • Cravings with compulsive use

How is nicotine the same/ different from other addictive drugs?

  • 85+% who use nicotine, use daily

– 10% of cocaine/etoh users

  • Withdrawal not life-threatening

– Can be for alcohol

  • Most severe consequences

delayed

  • ?

The Opportunity

  • Most tobacco users want to quit
  • Half make a serious attempt each year
  • 5-7% who quit on their own succeed
  • Assistance increases absolute success

15-40%

  • Only one in 5 use meds
  • one in 50 get counseling
  • 80% see a HCP each year
slide-3
SLIDE 3

3

MPH MD/HCP

Raising taxes Clean indoor air regulation Product regulation Denormalization

Population prevalence Greatest good from available resources Compare costs to: Individual treatment Maximize the probability of success Compare costs to:

Lung cancer treatment Cancer screening Substance abuse treatment Road repair

Treatment Perspective

MPH: How do we increase quit success in

a population (total quitters) ??

Increase use of evidence-based support during quit attempts Increase effectiveness

  • f evidence-based support

Increase quit attempts

Sweet Spot

Task Force on Community Preventive Services

  • Independent, nonfederal Task Force

– evidence-based – focus on non-clinical interventions

  • Reviewed 14 interventions to:*

– reduce ETS exposure – reduce tobacco use initiation – increase tobacco use cessation

*Am J Prev Med February 2001

Strategies to increase tobacco use cessation

  • Increasing unit price: strongly recommend
  • Mass media campaigns (combine w other)
  • strongly recommend
  • Health Care System-level interventions

– provider reminders: recommended – provider education: insuff evidence – provider remind + education: strong rec – reduce patient out-of-pocket costs: rec – multicomponent phone support: str. rec WHO recommends 3 treatment services for all countries

  • Primary-care advice to quit
  • Low-cost pharmacotherapy
  • Easily accessible and free quitlines
slide-4
SLIDE 4

4

Case Study: Mr G

  • 53 y.o male with

gradually increasing trouble breathing Past History:

  • High blood pressure
  • Smokes 1 pack/day

Social:

  • Married, 2 children,

non-smokers Insured Through Work:

  • No cessation benefit
  • A long-term condition
  • Stakes are high
  • Relapse is part of nicotine dependence

– 19/20 relapse without treatment – 2/3 relapse even with best treatment – not an indication of personal failure

The 5 A’s

  • ASK about tobacco use
  • ADVISE to quit
  • ASSESS willingness to make quit attempt
  • ASSIST in quit attempt
  • ARRANGE follow-up

Treatment Methods In Use

Counseling Group Counseling Telephone-based counseling 1:1 counseling Pharmacotherapy OTC Pharmacotherapy Rx Pharmacotherapy

slide-5
SLIDE 5

5

25

Washington State Quit Line

Available to all ― Half-hour coaching ― Triage Available to some ― Intensive Benefit: 4 calls & patches

Pharmacotherapy

  • Increases cessation

rates

  • Can increase use of

behavioral therapies

Pharmacologic Methods First-line Therapies

Three classes of FDA-approved drugs for smoking cessation

  • Nicotine replacement therapy (NRT)

– Nicotine gum, patch, lozenge, nasal spray, inhaler

  • Psychotropics

– Sustained-release bupropion

  • Partial nicotinic receptor agonist

– Varenicline

Nicotine Patch

  • Available in 7mg,

14mg, 21mg doses

  • Easy to use, conceal
  • Provides consistent

nicotine levels

  • Not recommended in

patients with serious skin conditions

slide-6
SLIDE 6

6

Nicotine Gum

  • Available in 2mg,

4mg doses

  • Patients can titrate

nicotine levels

  • Requires correct

technique

  • Not recommended

in patients with dentures

Nicotine Lozenge

  • Available in 2mg,

4mg doses

  • Patients can titrate

nicotine levels

  • A bit easier to use

than nicotine gum

  • Can have GI side

effects

What is Currently Approved?

Front Line Treatments available with Rx only:

  • Nicotine Inhaler
  • Nicotine Spray
  • bupropion
  • varenicline

Nicotine Inhaler

  • Mimics hand to

mouth action of smoking

  • Patient can titrate

nicotine levels

  • Possible initial

throat and mouth irritation

Nicotine Spray

  • Patient can titrate

nicotine levels

  • Quick onset of action
  • May be more effective

than other forms of NRT

  • Can result in

dependence

  • Side effects can be

significant

bupropion

  • Easy to use
  • As effective as patch
  • Might be useful in

patients with depression

  • Slight risk of seizure
  • Contraindicated in a

number of conditions

slide-7
SLIDE 7

7

varenicline

  • Reduces craving

and withdrawal

  • High efficacy
  • Different

mechanism than NRT

  • Can cause

nausea

varenicline – FDA Advisory

  • Use with caution in

patients with a history of psychiatric illness (includes depression).

  • May cause changes in

behavior or mood.

  • May impair ability to

drive or operate heavy machinery.

NRT: Can you use in combination?

  • Patch in combination with short acting (gum
  • r spray) more effective than either alone
  • Bupropion can be used with patch

+ =

Increased Success

Common Misconceptions

  • I should use as little NRT as

possible.

  • Medications are a “Magic Bullet”.
  • Nicotine will give me a heart attack.

NRT for Pregnancy and Youth

  • Evidence is

inconclusive

  • Determine if

benefits

  • utweigh the

risks.

Maximizing Treatment Success

2008 US PHS Guidelines

Medication plus counseling is the most effective treatment.

slide-8
SLIDE 8

8

What Should I Recommend?

  • Patient preference is

important.

  • Side-effect profiles vary.
  • Past experience may

predict future experience.

  • Combination therapy is

effective.

Treatment Access:

Convenient for us Inconvenient for smokers

Model for treating tobacco dependence

Why variation in reach?

  • Size of service and promotion budget
  • Efforts to markedly increase reach use via

revenue from tobacco taxes, health insurance or other sources have worked (up to 5-12%)

  • Editorial comment: Taxing tobacco users
  • n tobacco products and for healthcare

while not providing treatment is a human rights and policy issue!

Treatment Challenges

  • Who does it?
  • Who pays?
  • Mainstreaming
  • Overcoming Tobacco Control anti-

treatment biases

  • Avoiding hyper-medicalization
  • What the H*** are those 5 As again?
slide-9
SLIDE 9

9

In Conclusion

  • Effective treatments for tobacco

dependence exist

  • When made available without

barriers and publicized, treatments are used

  • Gap between effectiveness and

use is a social justice issue